Patent Description:
Immunodiagnostic reagents are the fastest-growing segment of in vitro diagnostic reagents, which achieve qualitative or quantitative detection through specific binding between an antigen and an antibody.

Polymyxins are currently the last choice for the clinical treatment of infections caused by multi-drug-resistant and pan-drug resistant Gram-negative bacteria. In recent years, due to the increasing clinical use of polymyxins, the number of polymyxin-resistant strains has increased year by year. Although the resistance of bacteria to polymyxins is not strong so far, the case of no cure may occur. How to effectively curb the spread of drug resistance has become a global public health issue.

Among a variety of drug resistance mechanisms, the mcr-<NUM> gene related to mediating the addition of lipid A phosphoethanolamine (PEtn) is discovered in various plasmids. Through the horizontal transference of a plasmid in different bacteria, the mcr-<NUM> gene even can coexist with other drug resistance genes in the same plasmid, and thus multiple drug resistance mechanisms are generated after expression. In addition, the unreasonable use of antibiotics makes the drug resistance of bacteria continue to increase, causing great trouble for clinicians to apply antibiotics. <CIT> discloses monoclonal antibodies reacting with melanocortin-<NUM> receptor protein (MCR-<NUM>) and their use in ELISA allowing detection of MCR-<NUM> positive bacteria in ground meats. Detection of colistin by ELISA and LFIA is also reported in <NPL>. Rapid detection of colistin resistance protein MCR-<NUM> by liquid chromatography tandem mass spectrometry LC-MS/MS is disclosed in <NPL>.

Laboratory detection of mcr-<NUM>-mediated polymyxin resistance is mainly conducted by molecular biotechnology. The research and development of products for the rapid diagnosis of mcr-<NUM> with independent intellectual property rights is of great significance for the rapid identification of polymyxin-resistant strains and resistance mechanisms thereof, the optimization of polymyxin treatment regimens, and the prolongation of a service life of polymyxins as the last-line treatment drug.

In order to solve the above technical problems, the present disclosure provides a mouse MCR-<NUM> protein-resistant hybridoma cell line, and a mAb and use thereof.

The present disclosure adopts the following technical solutions:.

A nucleic acid is provided, including nucleotides encoding the mouse anti-MCR-<NUM> protein antibody described above.

Preferably, a nucleotide sequence of the nucleic acid for encoding the light chain variable region of the antibody 1BH8 may be as shown in SEQ ID NO: <NUM>, and a nucleotide sequence of the nucleic acid for encoding the heavy chain variable region of the antibody 1BH8 may be as shown in SEQ ID NO: <NUM>; and.

A reagent comprising the mouse anti-MCR-<NUM> protein antibody described above for detecting an MCR-<NUM> protein antigen is provided.

Preferably, the mouse anti-MCR-<NUM> protein antibody may be used in an in vitro diagnostic kit or a microfluidic chip; and the in vitro diagnostic kit may be a colloidal gold immunoassay kit, a chemiluminescence kit, a radioimmunoassay kit, an enzyme-linked immunosorbent assay (ELISA) kit, or a fluoroimmunoassay kit.

Preferably, an immune colloidal gold test strip of a double-antibody sandwich method may be prepared, wherein the antibody 1BH8 is used as a coating antibody and the antibody 1BD9 is used as a gold-labeled antibody; or
the antibody 1BD9 is used as a coating antibody and the antibody 1BH8 is used as a gold-labeled antibody.

The present disclosure has the following advantages and positive effects: The present disclosure provides two mouse MCR-<NUM> protein-resistant hybridoma cell lines, which can produce two mouse anti-MCR-<NUM> protein antibodies. According to systematic evaluation including evaluation on antibody subtype and titer, and kit sensitivity, specificity, and stability, the mouse anti-MCR-<NUM> protein mAb shows excellent performance in all aspects, with a titer of more than <NUM>: <NUM>,<NUM>,<NUM>, and thus is suitable as an immunodiagnostic reagent for the preparation of an in vitro diagnostic kit.

The embodiments of the present disclosure will be described below.

The present disclosure relates to an antibody 1BH8 produced by a mouse MCR-<NUM> protein-resistant hybridoma cell line and an antibody 1BD9 produced by a mouse MCR-<NUM> protein-resistant hybridoma cell line.

The present disclosure discloses a mouse MCR-<NUM> protein-resistant hybridoma cell line named 1BH8 and a mouse MCR-<NUM> protein-resistant hybridoma cell line named 1BD9.

The antibody 1BH8 produced by a mouse MCR-<NUM> protein-resistant hybridoma cell line includes a light chain variable region and a heavy chain variable region, wherein the light chain variable region includes CDRL1 shown in SEQ ID NO: <NUM>, CDRL2 shown in SEQ ID NO: <NUM>, and CDRL3 shown in SEQ ID NO: <NUM>; and the heavy chain variable region includes CDRH1 shown in SEQ ID NO: <NUM>, CDRH2 shown in SEQ ID NO: <NUM>, and CDRH3 shown in SEQ ID NO: <NUM>; the light chain variable region may have an amino acid sequence shown in SEQ ID NO: <NUM>, and the heavy chain variable region may have an amino acid sequence shown in SEQ ID NO: <NUM>;.

A nucleotide sequence encoding the light chain variable region of the mouse anti-MCR-<NUM> protein antibody 1BH8 may be as shown in SEQ ID NO: <NUM>, and a nucleotide sequence encoding the heavy chain variable region of the antibody 1BH8 may be as shown in SEQ ID NO: <NUM>.

The antibody 1BD9 produced by a mouse MCR-<NUM> protein-resistant hybridoma cell line includes a light chain variable region and a heavy chain variable region, wherein the light chain variable region includes CDRL1 shown in SEQ ID NO: <NUM>, CDRL2 shown in SEQ ID NO: <NUM>, and CDRL3 shown in SEQ ID NO: <NUM>; and the heavy chain variable region includes CDRH1 shown in SEQ ID NO: <NUM>, CDRH2 shown in SEQ ID NO: <NUM>, and CDRH3 shown in SEQ ID NO: <NUM>, the light chain variable region may have an amino acid sequence shown in SEQ ID NO: <NUM>, and the heavy chain variable region may have an amino acid sequence shown in SEQ ID NO: <NUM>;.

A nucleotide sequence encoding the light chain variable region of the mouse anti-MCR-<NUM> protein antibody 1BD9 may be as shown in SEQ ID NO: <NUM>, and a nucleotide sequence encoding the heavy chain variable region of the antibody 1BH8 may be as shown in SEQ ID NO: <NUM>.

The mouse anti-MCR-<NUM> protein antibodies produced by the hybridoma cell line 1BH8 and the hybridoma cell line 1BD9 can be used as reagents to detect an MCR-<NUM> protein antigen. The mouse anti-MCR-<NUM> protein antibody shows prominent performance in all aspects, and thus is suitable as an immunodiagnostic reagent for the preparation of an in vitro diagnostic kit, and the in vitro diagnostic kit may be a colloidal gold immunoassay kit, a chemiluminescence kit, a radioimmunoassay kit, an ELISA kit, or a fluoroimmunoassay kit. Alternatively, the mouse anti-MCR-<NUM> protein antibody can be made into a microfluidic chip for detecting an MCR-<NUM> protein antigen.

To develop an MCR-<NUM> protein diagnostic reagent of the colloidal gold method, an MCR-<NUM> protein first needs to be extracted to obtain a high-purity antigen, the antigen is used to stimulate an excellent immune response in mice, and then the hybridoma technique is used to screen an antibody with high affinity and specificity for the development of related in vitro diagnostic reagents. The two antibodies involved in this solution are especially suitable for preparing an immune colloidal gold test strip of a double-antibody sandwich method, wherein the antibody 1BH8 is used as a coating antibody and the antibody 1BD9 is used as a gold-labeled antibody. The prepared immune colloidal gold test strip of a double-antibody sandwich method is more sensitive. Moreover, the antibody 1BH8 can be used as a gold-labeled antibody, and the antibody 1BD9 can be used as a coating antibody. The present disclosure is further described below through specific examples. Experimental methods for which operation steps are not specified are all conducted in accordance with the corresponding product instructions. The instruments, reagents, and consumables used in the examples can be purchased from commercial companies unless otherwise specified.

A mcr-<NUM> gene sequence was searched and downloaded from National Center for Biotechnology Information (NCBI), and a recombinant plasmid was transformed into Escherichia coli (E. coli) for induced expression. Purification was conducted by nickel-column affinity chromatography. Bacterial cells (with a wet weight of <NUM>) were resuspended in an equilibration buffer with pH <NUM> and then subjected to ultrasonication until a bacterial solution was clear, the bacterial solution was centrifuged at a high speed, and a resulting supernatant was filtered through a membrane and then passed through a nickel column to elute a target protein, which had a molecular weight consistent with the expected <NUM> KDa. A sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) result was shown in <FIG>. The protein was quantified by bicinchoninic acid (BCA) assay and then dispensed.

<NUM>-week-old female Balb/c mice were immunized with the purified MCR-<NUM> protein to prepare an antibody. The mice were divided into <NUM> groups according to the immunization dosage, with <NUM> mice in each group; according to an antigen content, a first group was immunized at an immunization dosage of <NUM>µg/mouse, and a second group was immunized at an immunization dosage of <NUM>µg/mouse. For an initial immunization, an appropriate amount of the MCR-<NUM> protein was taken and diluted with normal saline to <NUM>µL, then <NUM>µL of complete Freund's adjuvant (CFA) was added for thorough emulsification, and a resulting emulsion was subcutaneously injected into the mice (multi-point injection); two weeks later, the mice were subjected to a secondary immunization by intraperitoneal injection at the same dosage, with an adjuvant of incomplete Freund's adjuvant (IFA) instead; two weeks later, the mice were subjected to an additional immunization by intraperitoneal injection; <NUM> days later, blood was collected from the tail of mice, and a serum titer of the mice was determined by ELISA. Specific steps were as follows: An ELISA plate was coated overnight at <NUM> with the MCR-<NUM> protein of <NUM>µg/ml at <NUM>µL/well, spin-dried, and washed <NUM> times with phosphate-buffered saline with Tween <NUM> (PBST). <NUM>% skimmed milk powder was added at <NUM>µL/well to block at <NUM> for <NUM>. Blood was collected from the tail of the mice and then centrifuged at <NUM>,<NUM> rpm to obtain serum, and the serum was serially diluted from <NUM>: <NUM>,<NUM> to <NUM>:<NUM>,<NUM> with PBS for later use. The plate was spin-dried and then washed <NUM> times with PBST, a primary antibody diluted with PBS at <NUM>: <NUM>,<NUM> was added at <NUM>µL/well, and the plate was incubated at <NUM> for <NUM>. The plate was spin-dried and then washed <NUM> times with PBST, a goat anti-mouse secondary antibody diluted with PBS at <NUM>:<NUM>,<NUM> was added at <NUM>µL/well, and the plate was incubated at <NUM> for <NUM>. The plate was spin-dried and then washed <NUM> times with PBST, TMB was added at <NUM>µL/well, and the plate was incubated at <NUM> to allow a chromogenic reaction for <NUM>; the chromogenic reaction was stopped, and a value was read.

Three days before fusion, mice were subjected to a booster immunization by intraperitoneal injection at the same dosage as the previous immunization, without an adjuvant. Feeder cells were prepared one day before fusion. A Balb/c mouse <NUM>-<NUM> weeks old was selected, and eyeballs of the mouse were removed to collect blood; then the mouse was sacrificed by cervical dislocation, disinfected in <NUM>% alcohol for <NUM>, and fixed on a tray; and the abdominal skin was aseptically cut in a clean bench. <NUM> of an HAT selection medium was injected into the abdominal cavity of the mouse with a sterile syringe, the abdomen was slightly rubbed with an alcohol cotton ball, and the medium was drawn out. The medium was added to <NUM> of an HAT medium, and a resulting mixture was added to <NUM><NUM>-well cell culture plates at <NUM>µL/well, and then cultivated in a <NUM> and <NUM>% CO<NUM> incubator. One week before fusion, myeloma cells (Sp2/<NUM> cells) were recovered, cultivated in a PRMI-<NUM> medium with <NUM>% fetal bovine serum (FBS), and subcultivated in a <NUM> and <NUM>% CO<NUM> incubator. Cells in a logarithmic growth phase were collected into a centrifuge tube, subjected to cell counting, and diluted to <NUM><NUM> cells/ml for later use. The Balb/c mice that had been subjected to the booster immunization <NUM> days ago were taken, eyeballs were removed to collect blood and prepare positive serum, and the mice were sacrificed by cervical dislocation and disinfected with <NUM>% alcohol for <NUM>; then a spleen was aseptically collected in a clean bench and washed several times in a sterile dish, and a connective tissue was stripped. The spleen was placed on a microporous copper mesh, a fresh RPMI-<NUM> medium was added, and the medium was first drawn with a syringe and injected from an end of the spleen to blow off spleen cells; after the process was repeated several times, an inner plug of the syringe was used to gently grind the remaining spleen until there was no obvious red tissue mass. A spleen cell suspension in a dish was gently pipetted up and down, then transferred to a <NUM> centrifuge tube, and centrifuged at <NUM>,<NUM> r/min for <NUM> to collect spleen cells, and the spleen cells were counted for later use. The immunized mouse spleen cells and Sp2/<NUM> cells were mixed at a cell number ratio of <NUM>:<NUM>, added to a <NUM> centrifuge tube, and centrifuged at <NUM>,<NUM> r/min for <NUM>, a resulting supernatant was discarded, and the two cells were thoroughly mixed by rubbing gently in the palm of hands. The centrifuge tube was placed in a <NUM> blue-cap bottle filled with <NUM> hot water, and then <NUM> of preheated dimethyl sulfoxide (DMSO)/polyethylene glycol (PEG) was added dropwise to the fusion tube within <NUM>, during which the DMSO/PEG was added slowly first and then quickly, and the centrifuge tube was gently swirled. Then an antibiotic-free and serum-free RPMI-<NUM> medium was immediately added to stop the reaction, during which <NUM> of the medium was added in the first minute, <NUM> of the medium was added in the second minute, <NUM> of the medium was added in the third minute, and <NUM> of the medium was added in the fourth minute. A resulting mixture was incubated in a <NUM> water bath for <NUM> and then centrifuged at <NUM> r/min for <NUM>, and a resulting supernatant was discarded; a resulting precipitate was suspended with HAT, then thoroughly mixed with <NUM> of an HAT selection medium including <NUM>% calf serum preheated at <NUM>, and added to a <NUM>-well cell plate with feeder cells at <NUM>µL/well, and the cell plate was incubated in a <NUM> and <NUM>% CO<NUM> incubator. <NUM> days later, half of the medium in the cell plate was replaced with fresh HAT medium, and <NUM> days later, the medium was completely replaced with HT medium. Positive cells in the <NUM>-well plate were subcloned by limiting dilution analysis (LDA): feeder cells were prepared first according to the above method, and hybridoma cells to be cloned were taken and counted, then diluted to <NUM> to <NUM> cells/ml with HT medium, added at <NUM>µL/well to a <NUM>-well cell plate with the feeder cells (the cloning of each hybridoma cell line required a <NUM>-well cell plate), and cultivated in a <NUM> and <NUM>% CO<NUM> incubator; the number of clones in each cell well was counted and marked about <NUM> days later, the medium was replaced with fresh medium on day <NUM>, and a test was conducted when cells covered <NUM>/<NUM> to <NUM>/<NUM> of the entire bottom surface of each well; after <NUM> to <NUM> times of cloning, all cell wells of the <NUM>-well plate were positive, at which point the cells could be expanded and verified; the obtained two mouse MCR-<NUM> protein-resistant hybridoma cell lines were 1BH8 and 1BD9, respectively, which were cryopreserved. Hybridoma cells verified as positive were expanded and cryopreserved. A specific process was as follows: vigorously-growing hybridoma cells in prominent conditions were gently blown off from a flask with antibiotic-free and serum-free DMEM and then centrifuged at <NUM>,<NUM> r/min for <NUM>, and a resulting supernatant was discarded; a cryopreservation solution (with <NUM>% RPMI-<NUM> medium, <NUM>% FBS, and <NUM>% DMSO) was added to make cells uniformly dispersed, and a resulting cell suspension was then dispensed into cell cryopreservation tubes; then the cryopreservation tubes were placed in a cryopreservation box, the cryopreservation box was placed in a -<NUM> freezer, and one day later, the cryopreservation tubes were transferred to liquid nitrogen and related records were made.

<NUM> to <NUM>-week-old female Balb/c mice were injected intraperitoneally with sterile liquid paraffin at <NUM>/mouse, and <NUM> days later, the mice were injected intraperitoneally with hybridoma cells in a logarithmic growth phase at <NUM> × <NUM><NUM> cells/mouse. The mice were observed every day. About <NUM> to <NUM> days later, abdomens of the mice obviously bulged, at which point the lower abdominal skin was disinfected with a <NUM>% alcohol cotton ball and then the abdominal cavity was punctured with a <NUM>-gauge needle to collect an ascitic fluid. After an ascitic fluid was regenerated and accumulated, the ascitic fluid was collected once again. The collected ascitic fluid was centrifuged at <NUM>,<NUM> r/min for <NUM>, and a resulting clear middle layer was collected, filtered with filter paper, dispensed, and stored at -<NUM>.

The ascitic fluid was purified with a Protein-G column. Specific steps were as follows: <NUM> of the ascitic fluid was taken and centrifuged at <NUM>,<NUM>, and a resulting clear layer was collected and thoroughly mixed with <NUM> of a washing buffer to obtain a sample; <NUM>% ethanol was passed through the column, then the column was equilibrated with <NUM> of a washing liquid, and the sample was passed through the column at a flow rate of <NUM>/drop; the sample was repeatedly loaded <NUM> times, and then the column was washed with <NUM> of a washing buffer at a flow rate of <NUM>/drop; after the washing was completed, elution was conducted with <NUM> of an elution buffer, and after the elution was completed, a pH was adjusted to <NUM> with <NUM> Tris PH = <NUM>; then concentration was conducted with a concentration column, and a resulting concentrate was subjected to dialysis overnight at <NUM> with PBS in a <NUM> kd dialysis bag.

According to the instructions of the SIGMA kit, the mAb subtype identification was conducted by capture-ELISA. Specific steps were as follows: an mAb subtype identification reagent was diluted at <NUM>:<NUM>,<NUM>, added to an ELISA plate at <NUM>µL/well, and incubated at <NUM> for <NUM>; the plate was washed three times with PBST and pat-dried; the antibody was diluted at <NUM>: <NUM>,<NUM> and added at <NUM>µL/well, and then the plate was incubated at <NUM> for <NUM>; the plate was washed three times with PBST and pat-dried; an HRP enzyme-labeled goat anti-mouse IgG secondary antibody was diluted at <NUM>: <NUM>,<NUM> and added at <NUM>µL/well, and then the plate was incubated at room temperature for <NUM>; a chromogenic reaction was conducted for <NUM> to <NUM>. A subtype reagent added in a well with an OD450 reading significantly higher than that of other wells indicated the subtype of the mAb. The antibody subtype of the antibodies 1BH8 and 1BD9 was IgG1.

The antibody titer was determined after purification was conducted by indirect ELISA. Specific steps were as follows: the MCR-<NUM> protein was diluted to <NUM>µg/mL and added to an ELISA plate at <NUM>µL/well to coat overnight at <NUM>, where an uncoated control was set; the plate was spin-dried and then washed <NUM> times with PBST; <NUM>% skimmed milk powder was added at <NUM>µL/well to block at <NUM> for <NUM>; the plate was spin-dried and then washed <NUM> times with PBST; the antibody (with a concentration of <NUM>/ml) was serially diluted from <NUM>: <NUM>,<NUM> to obtain a total of <NUM> gradient concentrations, resulting antibody dilutions were each added to the plate at <NUM>µL/well, and the plate was incubated at <NUM> for <NUM>, where an uncoated control was set; the plate was spin-dried and then washed <NUM> times with PBST, a goat anti-mouse secondary antibody diluted with PBS at <NUM>:<NUM>,<NUM> was added at <NUM>µL/well, and the plate was incubated at <NUM> for <NUM>; the plate was spin-dried and then washed <NUM> times with PBST, TMB was added at <NUM>µL/well, and the plate was incubated at <NUM> to allow a chromogenic reaction for <NUM>; the chromogenic reaction was stopped, and a value was read. After the purification, when the antibody was diluted to <NUM>/ml, a titer reached more than <NUM>: <NUM>,<NUM>,<NUM>.

SDS-PAGE was used to identify the molecular weight and purity of the antibody. Gels were prepared, where a separation gel was <NUM>% and a stacking gel was <NUM>%; <NUM>µL of a sample and <NUM>µL of a buffer were thoroughly mixed and boiled for <NUM> to obtain a sample solution; <NUM>µL of the sample solution was loaded in each well, and a prestained protein Marker control was set; electrophoresis was conducted at <NUM> V for <NUM> and at <NUM> V for <NUM>; after the electrophoresis was completed, a Coomassie brilliant blue (CBB) solution was added for staining; destaining was conducted by boiling in deionized water <NUM> times, with <NUM> each time; a purified mAb was identified by SDS-PAGE, and resulting bands were clear, without impurity bands. As shown in <FIG>, there were clear bands at <NUM> KDa and <NUM> KDa.

An Ig variable region gene was cloned by RT-PCR. Total RNA was extracted from the hybridoma cell lines 1BD9 and 1BH8 by the Trizol method (purchased from Invitrogen), and was reverse-transcribed into a cDNA library with M-MLV reverse transcriptase (purchased from Invitrogen).

Upstream primer for a heavy chain framework region.

PCR conditions were as follows: pre-denaturation at <NUM> for <NUM>; repeating the following cycle <NUM> times: <NUM> for <NUM>, <NUM> for <NUM>, and <NUM> for <NUM>; and finally, extension at <NUM> for <NUM>.

VL and VH fragments were separated and recovered by agarose gel electrophoresis. The recovered VL and VH fragments were ligated with a pMD19-T (sKPCle) vector (Takara), and a ligation system was as follows:
VL PCR product/VH PCR product: each <NUM> ng; pMD19-T (sKPCle) vector: <NUM>µL; Solution I ligation reaction solution: <NUM>µL; and ddH<NUM>O: making up to <NUM>µL. The ligation was conducted overnight at <NUM>.

A ligation product was transformed into E. coli DH5α competent cells, the competent cells were cultivated overnight at <NUM>, single colonies were picked and cultivated at <NUM> under shaking for <NUM>, and then a resulting bacterial solution was subjected to PCR identification. cDNA of a corresponding antibody was used as a positive control. A reaction system (<NUM>µL) was prepared as follows:
bacterial solution: <NUM>µL; upstream primer (<NUM>): <NUM>µL; downstream primer (<NUM>): <NUM>µL; dNTP Mixture (each <NUM>): <NUM>µL; Taq DNA polymerase (<NUM> U/µL): <NUM>µL; <NUM> × Taq Buffer (Mg<NUM>+ plus): <NUM>µL; and water: making up to <NUM>µL. Reaction conditions were the same as above.

PCR-positive clones were selected for expansion, and a plasmid was extracted from the positive clones with a plasmid extraction kit (Takara) and sequenced. At least <NUM> clone samples were sequenced for each chain of each antibody until at least three samples had the same sequencing result. The heavy chain and light chain variable region sequences of the antibodies 1BD9 and 1BH8 were successfully cloned, which were consistent with the characteristics of typical antibody variable region sequences according to alignment.

An immune colloidal gold test strip of a double-antibody sandwich method was prepared as follows:.

The MCR-<NUM> protein test card of the colloidal gold method prepared by the above method was taken, and a blank sample, an MCR-<NUM> protein, and an MCR-<NUM> protein-containing positive sample were each spotted on the test card. Results were shown in <FIG>, where test results of the blank sample, the MCR-<NUM> protein, and the MCR-<NUM> protein-containing positive sample were shown from left to right, respectively. It can be seen that the test result of the blank sample was negative, and the test results of the MCR-<NUM> protein and the MCR-<NUM> protein-containing positive sample were all positive, indicating that the MCR-<NUM> protein test card of the colloidal gold method prepared by this solution can detect an MCR-<NUM> protein and a corresponding positive sample.

Claim 1:
A mouse anti-MCR-<NUM> protein antibody, wherein the mouse anti-MCR-<NUM> protein antibody is: an antibody 1BH8 comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises complementary-determining region (CDR) L1 shown in SEQ ID NO: <NUM>, CDRL2 shown in SEQ ID NO: <NUM>, and CDRL3 shown in SEQ ID NO: <NUM>; and the heavy chain variable region comprises CDRH1 shown in SEQ ID NO: <NUM>, CDRH2 shown in SEQ ID NO: <NUM>, and CDRH3 shown in SEQ ID NO: <NUM>, the light chain variable region has an amino acid sequence shown in SEQ ID NO: <NUM>, and the heavy chain variable region has an amino acid sequence shown in SEQ ID NO: <NUM>;
or,
an antibody 1BD9 comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDRL1 shown in SEQ ID NO: <NUM>, CDRL2 shown in SEQ ID NO: <NUM>, and CDRL3 shown in SEQ ID NO: <NUM>; and the heavy chain variable region comprises CDRH1 shown in SEQ ID NO: <NUM>, CDRH2 shown in SEQ ID NO: <NUM>, and CDRH3 shown in SEQ ID NO: <NUM>, the light chain variable region has an amino acid sequence shown in SEQ ID NO: <NUM>, and the heavy chain variable region has an amino acid sequence shown in SEQ ID NO: <NUM>.